1E,6E)-1,7-Bis(3,4-dimethoxyphenyl)-4-cyclobutylmethyl-1,6-heptadiene-3,5-dione or [(1E, 4Z,6E)-4-(cyclobutylmethyl)-1,7-bis(3,4-dimethoxyphenyl)-5-hydroxyhepta-1,4,6-trien-3-one]

1E,6E)-1,7-Bis(3,4-dimethoxyphenyl)-4-cyclobutylmethyl-1,6-heptadiene-3,5-dione or [(1E, 4Z,6E)-4-(cyclobutylmethyl)-1,7-bis(3,4-dimethoxyphenyl)-5-hydroxyhepta-1,4,6-trien-3-one]
Trade Name
Orphan Indication Spinal muscular atrophy
USA Market Approval USA
USA Designation Date 2016-02-17 00:00:00
Sponsor Allianz Pharmascience Ltd.;8630 Fenton Street, Suite 724;Silver Spring, Maryland, 20910
Related Access Program
Pfizer – Non Small Cell Lung Cancer With ALK or ROS1 Rearrangement Pfizer – Non Small Cell Lung Cancer Harboring Molecular Alterations Biogen – Infantile-onset Spinal Muscular Atrophy Novartis Pharmaceuticals – Non-small Cell Lung Cancer (NSCLC) Biogen – Infantile-onset Spinal Muscular Atrophy (SMA)